Change in Opioid Use after the Initiation of Gabapentin Therapy in Patients with Postherpetic Neuralgia

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2809-2821

  Berger, Ariel ^a   Dukes, Ellen ^b   McCarberg, Bill ^c   Liss, Marty ^a   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PFIZER INC   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Gabapentin; Neuralgia; Opioid analgesics; Pharmacotherapy herpes zoster

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; DRUG; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; LONG ACTING DRUG; METHADONE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; OPIATE AGONIST; OXYCODONE; PENTAZOCINE; PETHIDINE; SHORT ACTING DRUG; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; COMORBIDITY; DRUG FORMULATION; DRUG UTILIZATION; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; MALE; POSTHERPETIC NEURALGIA; PRESCRIPTION; REIMBURSEMENT;

EID: 0345095480     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80335-1     Document Type: Article

References (30)

1. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
2. Brown GR. Herpes zoster: Correlation of age, sex, distribution, neuralgia, and associated disorders. South Med J. 1976;69:576-578.
3. de Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Dermatol. 1957;75:193-196.
4. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: Clinical review and current management. Ann Neurol. 1986;20:651-664.
5. Watson CP, Evans RJ, Watt VR, Birkett N. Post-herpetic neuralgia: 208 cases. Pain. 1988;35:289-297.
6. Bonezzi C, Demartini L. Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl. 1999;173:25-35.
7. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(Suppl 2):S101-S105.
8. Thompson M, Bones M. Nontraditional analgesics for the management of postherpetic neuralgia. Clin Pharm. 1985;4:170-176.
9. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in postherpetic neuralgia: A single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988;43:363-371.
10. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38:1427-1432.
11. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41:1024-1028.
12. De Benedittis G, Besana F, Lorenzetti A. A new topical treatment for acute herpetic neuralgia and post-herpetic neuralgia: The aspirin/diethyl ether mixture. An open-label study plus a double-blind controlled clinical trial. Pain. 1992;48:383-390.
13. Max MB. Treatment of post-herpetic neuralgia: Antidepressants. Ann Neurol. 1994;35(Suppl):S50-S53.
14. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837-1842.
15. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology. 2002;59:1015-1021.
16. Rice AS, Maton S, for the Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomized, double blind, placebo controlled study. Pain. 2001;94:215-224.
17. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50(Suppl 6):S205-S224.
18. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003:2563-2568.
19. Professional ICD-9-CM Code Book. 6th ed. Reston, Va: St. Anthony Publishing; 2000.
20. Current Procedural Terminology. 4th ed. Chicago: American Medical Association; 2003.
21. HCPCS 2003. Salt Lake City, Utah: Ingenix, Inc; 2002.
22. Cohen HE, ed. Drug Topics Red Book 2003. 107th ed. Montvale, NJ: Medical Economics Company; 2003.
23. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain. Am J Public Health. 1992;82:243-248.
24. Quam L, Ellis LB, Venus P, et al. Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care. 1993;31:498-507.
25. Jollis JG, Ancukiewicz M, DeLong ER, et al. Discordance of databases designed for claims payment versus clinical information systems: Implications for outcomes research. Ann Intern Med. 1993;119:844-850.
26. Cooper GS, Yuan Z, Stange KC, et al. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care. 1999;37:436-444.
27. Cooper GS, Yuan Z, Stange KC, Rimm AA. Use of Medicare claims data to measure county-level variations in the incidence of colorectal carcinoma. Cancer. 1998;83:673-678.
28. Jencks SF, Williams DK, Kay TL. Assessing hospital-associated deaths from discharge data: The role of length of stay and comorbidities. JAMA. 1988;260:2240-2246.
29. Greenfield S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data. The hazards of ignoring comorbid disease. JAMA. 1988;260:2253-2255.
30. Hsia DC, Krushat WM, Fagan AB, et al. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system [erratum in N Engl J Med. 1990;322:1540]. N Engl J Med. 1988;318:352-355.